Recent developments highlight VolitionRx's progress in cancer detection technology, reimbursement efforts, strategic partnerships, and capital raising activities.

• VolitionRx's Capture-Seq technology demonstrated over 95% detection of early-stage cancers, indicating advancement in diagnostic capabilities [N1].
• The company advanced its Nu.Q cancer assay program with a reimbursement submission in France, supporting market access efforts [N2].
• VolitionRx signed a co-marketing agreement with Hologic for the Nu.Q Discover service, enhancing commercial collaboration [N11].
• The company completed a public offering of 11.55 million shares and warrants at $0.52 per set, providing capital but resulting in share price decline [N8].
• Multiple analyst firms, including D. Boral Capital and HC Wainwright & Co., maintained buy recommendations on VolitionRx, reflecting positive market sentiment [N3][N4][N5][N6][N7].

VolitionRx has demonstrated technological progress with its Capture-Seq platform showing over 95% detection rates for early-stage cancers, indicating potential clinical relevance. The advancement of the Nu.Q cancer assay program, including reimbursement submissions in France, suggests steps toward broader market access. Strategic partnerships, such as the co-marketing agreement with Hologic, may enhance commercialization efforts. Continued innovation and successful regulatory and reimbursement milestones could support the company's growth trajectory in the oncology diagnostics sector.

The company reported significant net losses and limited liquidity as of the end of 2025, with a current ratio of 0.17 and cash ratio of 0.09, indicating potential financial constraints. VolitionRx is currently not in compliance with certain NYSE American listing standards and must regain compliance by August 2027, posing a risk to its continued listing. The diagnostic market is competitive and subject to regulatory and reimbursement challenges, which may impact the company's ability to commercialize its products effectively. Execution risks include achieving market adoption, regulatory approvals, and financial sustainability.

VolitionRx's moat is centered on its proprietary cancer detection technologies, including Capture-Seq and the Nu.Q assay program, which target early-stage cancer detection. The company's strategic partnerships, such as the co-marketing agreement with Hologic, and its ongoing reimbursement submissions in key markets like France, support its commercial positioning. However, the company faces challenges related to financial sustainability and regulatory compliance, which may impact its competitive advantage. The specialized nature of its diagnostic assays and the potential clinical utility provide some differentiation in the oncology diagnostics market.

• Financial Sustainability: The company reported a net loss of $23.36 million for fiscal year 2025 and has limited liquidity, with a current ratio of 0.17 and cash ratio of 0.09 as of December 31, 2025, indicating potential challenges in funding ongoing operations.
• Regulatory and Listing Compliance: VolitionRx is not currently in compliance with NYSE American listing standards related to stockholders' equity and must regain compliance by August 6, 2027, or face potential delisting.
• Market Adoption and Commercialization: The company faces risks in achieving market acceptance of its diagnostic assays, navigating reimbursement pathways, and competing in a crowded oncology diagnostics market.

• VolitionRx Limited is a Delaware corporation with principal executive offices in Henderson, Nevada, USA.
• The company is listed on the NYSE American exchange under the ticker VNRX.
• As of April 28, 2026, there were 8,087,955 shares of common stock issued and outstanding, adjusted for a one-for-twenty reverse stock split effective April 28, 2026.
• The company operates subsidiaries including Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., Volition Global Services SRL, and majority owned Volition Veterinary Diagnostics Development LLC.
• The company develops cancer detection assays, including the Nu.Q cancer assay program, with recent reimbursement submission in France.
• VolitionRx's Capture-Seq technology shows over 95% detection of early-stage cancers, indicating a focus on early cancer diagnostics.
• The company has entered into a co-marketing agreement with Hologic for the Nu.Q Discover service.
• VolitionRx completed a public offering of 11.55 million shares and warrants at $0.52 per set in October 2025.
• The company has been subject to NYSE American listing compliance issues but submitted a plan to regain compliance by August 6, 2027.
• Financial snapshot for fiscal year ended December 31, 2025: revenue of $1.73 million USD, net loss of $23.36 million USD, cash and equivalents of approximately $1.12 million USD, current assets of $2.06 million USD, and current liabilities of $12.23 million USD.
• Liquidity ratios as of December 31, 2025: current ratio of 0.17 and cash ratio of 0.09, indicating limited short-term liquidity.
• The company reported diluted EPS of -$0.05 for the quarter ended September 30, 2025.
• The board of directors includes experienced executives with backgrounds in biotechnology, diagnostics, and business development, including CEO Cameron Reynolds and non-executive Chairman Timothy Still.
• The company is not classified as a large accelerated filer or emerging growth company, and it files reports with the SEC including 10-K/A and 8-K filings.
• VolitionRx has ongoing efforts to commercialize its diagnostic products and expand market access, including reimbursement submissions and strategic partnerships.